Zai Lab Ltd. (ZLAB) and Innoviva Specialty Therapeutics announced Monday that China's National Medical Products Administration or NMPA has approved Zai Lab's New Drug Application for XACDURO (sulbactam-durlobactam) to treat hospital-acquired and ventilator-associated pneumonia caused by Acinetobacter baumannii-calcoaceticus complex in China.

Related Keywords

China , Chinese , Harald Reinhart , Entasis Therapeutics Inc , China National Medical Products Administration , Head Of Global Development , Zai Lab , Zai Lab New Drug Application , Drug Administration , Zai Lab Ltd , More Such Health News , World Health Organization , Innoviva Specialty Therapeutics , National Medical Products Administration , New Drug Application , Greater China , Global Development , Infectious Diseases ,